Prescribing Guides
Metoprolol Prescribing Guide for Indian Clinical Practice
Metoprolol prescribing guide for Indian clinicians covering beta-blocker pharmacology, tartrate vs succinate, dosing, and NEET PG cardiology points.
MedNext Editorial Team | 2026-08-01 | 8 min read
Metoprolol Prescribing Guide for Indian Clinical Practice
Metoprolol prescribing guide for Indian clinicians covering beta-blocker pharmacology, tartrate vs succinate, dosing, and NEET PG cardiology points.
Metoprolol is a cardioselective beta-1 blocker widely used in Indian cardiology practice for hypertension, angina, heart failure, and arrhythmias. Understanding the difference between tartrate and succinate formulations is essential for safe prescribing.
Clinical Pharmacology Overview
Metoprolol selectively blocks beta-1 adrenergic receptors in the heart, reducing heart rate, contractility, and myocardial oxygen demand. At therapeutic doses, it has minimal beta-2 blocking effect (preserving bronchial and vascular smooth muscle relaxation), but selectivity is lost at higher doses.
Pharmacokinetics: Well absorbed orally with approximately 50% bioavailability (significant first-pass metabolism). Protein binding is 12%. Extensively metabolised in the liver by CYP2D6. Half-life is 3-7 hours (tartrate) and effectively 14-24 hours (succinate XR due to formulation). Primarily renally excreted as metabolites.
Indian Brand Names
- Betaloc (AstraZeneca) -- tartrate and succinate formulations
- Met XL (Sun Pharma) -- succinate XR
- Metolar (Cipla)
- Cardivas (Torrent) -- note: this is also a brand for carvedilol; verify formulation
- Metosartan (combination with telmisartan, by Cipla)
Approved Indications in Indian Clinical Practice
- Hypertension
- Stable angina pectoris
- Heart failure with reduced ejection fraction (succinate XR formulation)
- Acute myocardial infarction (to reduce mortality and reinfarction)
- Supraventricular tachycardia and rate control in atrial fibrillation/flutter
- Migraine prophylaxis
- Thyrotoxicosis (symptomatic control of tachycardia)
- Essential tremor
Dosing in Adults
Hypertension (tartrate): 50-100 mg orally twice daily. Maximum: 200 mg twice daily.
Hypertension (succinate XR): 25-100 mg once daily. Maximum: 200 mg once daily.
Angina (tartrate): 50-100 mg two to three times daily.
Heart failure (succinate XR ONLY): Start 12.5-25 mg once daily. Uptitrate every 2 weeks to target 200 mg once daily as tolerated. Never initiate during acute decompensation.
Acute MI: 5 mg IV every 5 minutes for 3 doses (if tolerated), then 50 mg orally every 6 hours for 48 hours, then 100 mg twice daily.
Rate control in AF: 25-100 mg two to three times daily (tartrate) titrated to heart rate.
Important Drug Interactions
- Verapamil, diltiazem: risk of severe bradycardia, AV block, and heart failure -- avoid combination
- Digoxin: additive AV nodal depression
- CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine): increase metoprolol levels significantly
- Clonidine: if both used, withdraw beta-blocker first to avoid rebound hypertension crisis
- Insulin and oral hypoglycaemics: beta-blockers mask hypoglycaemic symptoms (tachycardia, tremor) -- sweating is preserved
- Anaesthetic agents: additive myocardial depression
Side Effects and Monitoring
Common: fatigue, cold extremities, dizziness, bradycardia, weight gain, exercise intolerance.
Serious: severe bradycardia, AV block, acute heart failure decompensation (if started too aggressively), bronchospasm (dose-dependent loss of selectivity), masking of hypoglycaemia.
Monitoring: heart rate and blood pressure regularly. ECG if arrhythmia concern. Blood glucose in diabetics. Taper gradually over 1-2 weeks when discontinuing.
Special Populations
Pregnancy: Category C. Not first-line in pregnancy (labetalol is preferred for hypertension in pregnancy). Can cause foetal bradycardia and IUGR. Use only if benefit outweighs risk.
Renal impairment: No dose adjustment needed (hepatically metabolised).
Hepatic impairment: Bioavailability increases significantly due to reduced first-pass metabolism. Start at lower doses.
Elderly: Start low, titrate slowly. Higher sensitivity to bradycardia and CNS effects.
NEET PG High-Yield Points
- Cardioselective (beta-1 selective) -- selectivity lost at high doses
- Metoprolol succinate XR: mortality benefit in HFrEF (MERIT-HF trial)
- Three beta-blockers proven in HF: metoprolol succinate, bisoprolol, carvedilol
- Metabolised by CYP2D6 -- polymorphisms affect drug levels
- Beta-blockers mask hypoglycaemia symptoms except sweating
- Never combine with verapamil/diltiazem IV (cardiac arrest risk)
- Rebound tachycardia on abrupt withdrawal
- Tartrate (short-acting, BID-TID) vs succinate (long-acting, OD) -- not interchangeable
- IV metoprolol used in acute MI (within 24 hours) and SVT
Indian Regulatory Status
Metoprolol is a Schedule H drug under the Drugs and Cosmetics Act. Both tartrate and succinate formulations are available as single-ingredient and in fixed-dose combinations (e.g., with amlodipine or telmisartan). It is included in the NLEM. Price is controlled under DPCO for formulations on the essential medicines list.
Frequently Asked Questions
What is the difference between metoprolol tartrate and metoprolol succinate?
Metoprolol tartrate is immediate-release and dosed 2-3 times daily (used acutely and for angina/hypertension). Metoprolol succinate is extended-release (XR/XL) and dosed once daily (preferred for heart failure -- the MERIT-HF formulation). They are not interchangeable on a milligram-for-milligram basis.
Is metoprolol safe in asthmatics?
Metoprolol is beta-1 selective but selectivity is dose-dependent and lost at higher doses. It should be used with caution in mild asthma and is generally avoided in moderate-to-severe asthma or acute bronchospasm. If a cardioselective beta-blocker is essential, start very low and monitor closely.
Can metoprolol be stopped suddenly?
No. Abrupt withdrawal can cause rebound tachycardia, hypertension, angina exacerbation, and even myocardial infarction due to beta-receptor upregulation. Always taper over 1-2 weeks.
What is the role of metoprolol in heart failure?
Metoprolol succinate XR (not tartrate) is one of three beta-blockers with mortality benefit in heart failure with reduced ejection fraction (MERIT-HF trial). Start at a very low dose (12.5-25 mg daily) and uptitrate slowly over weeks to months to the target dose of 200 mg daily.
Continue reading
Prescribing GuidesMetformin Prescribing Guide for Indian Clinical Practice
Evidence-based metformin prescribing for Indian clinicians covering dosing, brands, interactions, monitoring and NEET PG high-yield points.
Prescribing GuidesCeftriaxone Prescribing Guide for Indian Clinical Practice
Complete ceftriaxone prescribing reference for Indian clinicians covering indications, dosing, reconstitution, drug interactions and NEET PG points.
Prescribing GuidesAmoxicillin Prescribing Guide for Indian Clinical Practice
Comprehensive amoxicillin prescribing reference for Indian doctors covering dosing, brands, resistance patterns and NEET PG high-yield pharmacology.
Continue with Prescribing Guides
Apply what you have read with clinical prescribing MCQs that test real decision-making: drug choice, dose selection, interactions and monitoring.
Try prescribing questionsBrowse all prescribing guides

